Liposomal siRNA for ovarian cancer.

Discovery of RNA interference (RNAi) has been one of the most important findings in the last ten years. In recent years, small interfering RNA (siRNA)-mediated gene silencing is beginning to show substantial promise as a new treatment modality in preclinical studies because of its robust gene selective silencing. However, until recently, delivery of siRNA in vivo was a major impediment to its use as a therapeutic modality. We have used a neutral liposome, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), for highly efficient in vivo siRNA delivery. Using siRNA tagged with Alexa-555, incorporated in DOPC liposomes, we have demonstrated efficient intra-tumoral delivery following either intraperitoneal or intravenous injection. Furthermore, EphA2-targeted siRNA in DOPC liposomes showed significant target modulation and anti-tumor efficacy.

[1]  A. Sood,et al.  EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma , 2004, Clinical Cancer Research.

[2]  A. Sood,et al.  EphA2 as a target for ovarian cancer therapy , 2005, Expert opinion on therapeutic targets.

[3]  Akira Ishizuka,et al.  Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. , 2004, Genes & development.

[4]  H. Maeda,et al.  Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. , 2003, Advances in experimental medicine and biology.

[5]  Yang Wang,et al.  Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[6]  T. Tuschl,et al.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. , 2004, Molecular cell.

[7]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[8]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.

[9]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[10]  S. Kaul,et al.  Vectors for RNA interference. , 2004, Current opinion in molecular therapeutics.

[11]  C. Miller,et al.  Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. , 1998, Biochemistry.

[12]  I. Fidler,et al.  Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice , 1998, Cancer and Metastasis Reviews.

[13]  J. G. Patton,et al.  siRNA therapeutics: big potential from small RNAs , 2005, Gene Therapy.

[14]  Anil K Sood,et al.  Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer , 2006, Cancer biology & therapy.

[15]  H. Maeda,et al.  Macromolecular Therapeutics , 2003, Clinical pharmacokinetics.

[16]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[17]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.